Table 1.
Baseline characteristics of included study
| Trial (year) | Treatment group | Patients (n) | Age (y) | Male (n, %) | BMI (kg/m2) | Paroxysmal (n %) | CHA2DS2‐VASc | Echocardiographic parameters | Co‐morbidities | Follow (M) | Design | NOS | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LA size, (cm) | LVEF (%) | Hy, (n %) | DM, (n %) | Pri‐CVA (n %) | CAD, (n %) | |||||||||||
| Cha et al. (2011) 15 | HFpEF + Ablation | 157 | 62.2 (54.4, 70.5) | 107 (68) | NR | 78 (50) | NR | 40 (35, 50)a | 62 (60, 65) | 75 (48) | 15 (10) | 8 (5) | 27 (17) | 12 | Prospective | 9 |
| No HF + Ablation | 100 | 52.8 (43.9, 59.7) | 75 (75) | NR | 61 (61) | NR | 25 (22, 28)a | 63 (60, 65) | 29 (29) | 5 (5) | 4 (4) | 15 (15) | ||||
| Aldaas et al. (2020)2 | HFpEF + Ablation | 51 | 67.6 (56.6, 74.7) | 31 (60.8) | 29.7 (24.9, 34.8) | 25 (49) | 3.0 (2.0, 4.0) | 4.2 (3.9, 4.9) | 58 (52, 65) | 38 (75) | 8 (16) | 5 (10) | 19 (37) | 50.9 (24.5, 62.3) | Retrospective | 8 |
| No HF + Ablation | 456 | 64.3 (57.6, 70.5) | 307 (67.3) | 27.8 (25.0, 31.0) | 331 (74) | 2.0 (1.0, 3.0) | 4.0 (3.7, 4.5) | 64 (60, 68) | 243 (53) | 44 (10) | 38 (8) | 51 (11) | 31.3 (9.2, 57.3) | |||
| Rattka et al. (2020) 18 | HFpEF + Ablation | 35 | 69 ± 9 | 14 (40) | 29 ± 6 | 27 (77.1) | NR | NR | NR | 28 (80.0) | 5 (14.3) | 2 (5.7) | 13 (37.1) | 29 ± 20 | Retrospective | 7 |
| No HF + Ablation | 150 | 64 ± 12 | 87 (58) | 28 ± 5 | 105 (70.0) | NR | NR | NR | 115 (76.7) | 18 (12.0) | 14 (9.3) | 51 (34.0) | ||||
| Yamauchi et al. (2021) 17 | HFpEF + Ablation | 293 | 69.6 ± 7.9 | 196 (66.9) | 24.4 ± 3.9 | 61 (48.8) | 2.80 ± 1.50 | 43.5 ± 5.7 | 63.0 ± 6.4 | 190 (64.8) | 64 (21.8) | 23 (7.8) | 31 (10.6) | 12 | Retrospective | 9 |
| No HF + Ablation | 125 | 64.2 ± 9.8 | 109 (87.2) | 25.2 ± 3.6 | 189 (64.7) | 1.76 ± 1.43 | 42.3 ± 6.0 | 62.8 ± 5.5 | 66 (52.8) | 23 (18.4) | 7 (5.6) | 11 (8.8) | ||||
| Rattka et al. (2021) 16 | HFpEF + Ablation | 43 | 73 ± 7 | 19 (44) | 28 (26, 30) | 26 (60) | 4 (3, 5) | 46.7 ± 7.4 | 65.3 (55.0,68.0) | 39 (91) | 10 (23) | 7 (16) | 28 (65) | 35 ± 22 | Case‐control | 8 |
| HFpEF + Medical | 43 | 74 ± 7 | 19 (44) | 29 (25, 31) | 22 (51) | 4 (3, 5) | 48.2 ± 7.5 | 65.6 (58.6,72.2) | 39 (91) | 11 (26) | 2 (5) | 27 (63) | ||||
| Fukui et al. (2020) 20 | HFpEF + Ablation | 35 | 70 ± 8 | 23 (66) | NR | 14 (40) | NR | 42 ± 6 | 62 ± 8 | 21 (55) | 8 (21) | NA | 1 (3) | 703 ± 424 d | Retrospective | 8 |
| HFpEF + Medical | 50 | 71 ± 13 | 32 (64) | NR | 19 (38) | NR | 43 ± 6 | 61 ± 9 | 32 (46) | 20 (29) | NA | 6 (12) | ||||
| Machino‐Ohtsuka et al. (2019)24 | HFpEF + Ablation | 79 | 68 ± 7 | 47 (59.5) | 24.6 ± 4.2 | NA | 3.9 ± 1.3 | 51 ± 21b | 65 ± 8 | 59 (74.7) | 27 (34.1) | 13 (16.5) | 10 (12.7) | 24 (12, 36) | Retrospective | 9 |
| HFpEF + Medical | 79 | 68 ± 9 | 49 (62) | 24.3 ± 4.3 | NA | 4.0 ± 1.5 | 51 ± 21b | 65 ± 8 | 62 (78.5) | 30 (38.0) | 14 (17.7) | 10 (12.7) | 24 (11, 37) | |||
Note: Values are reported as the mean ± SD, medians (interquartile range), or n (%).
Abbreviations: BMI, body mass index; CAD, coronary artery disease; d, day; DM, diabetes mellitus; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; Hy, hypertension; LA, left atrium, LVEF, left ventricular ejection fraction; M, month; NOS, Newcastle‐Ottawa Quality Assessment Scale; NR, not recorded; Pri‐CVA, prior cerebral vascular accident; Y, year.
a
Evaluate left atrial by LA volume index (cm3/m2).
b
Evaluate left atrial by left atrial volume (cm2).